Actively Recruiting
Evaluating One vs Two-Probe Thermal Ablation for Cervical Precancer Treatment in Women Living With HIV in Rwanda
Led by Fred Hutchinson Cancer Center · Updated on 2026-11-03
300
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Cervical cancer disproportionately affects women living with HIV WLWH in low- and middle-income countries, including Rwanda, where WLWH have a sixfold higher risk compared to the general population. Researchers are evaluating a new approach using thermal ablation TA with two probes to treat cervical precancerous lesions among WLWH. This feasibility study aims to provide evidence to improve treatment outcomes and support Rwandas goal to eliminate cervical cancer by 2027. Participants who test positive for high-risk HPV or visual inspection with acetic acid undergo further clinical exams, including biopsies and digital imaging. Eligible women with a type 1 transformation zone will be randomly assigned to receive TA treatment either with one probe or with two probes. Follow-up occurs at six months to assess persistent HPV and treatment effects. Women not eligible for TA will be referred for local care. During the study, participants complete screening tests and clinical exams at enrollment and return for a six-month follow-up visit with HPV testing, biopsies, and visual cervical assessment. Researchers will measure the proportion of women with persistent HPV at six months to evaluate treatment success. The study, supported by Fred Hutchinson Cancer Center, lasts from October 2026 to May 2028.
CONDITIONS
Brief Title
Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 Rwanda
Research Team
A
Araceli Loera, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here